IMVT-1401-2401
無料
2.12.7 (33)for iPhone, iPad and more
Age Rating
IMVT-1401-2401 スクリーンショット
About IMVT-1401-2401
The Immunovant eCOA App is intended for use to collect weekly study dosing information in a dosing diary relating to the IMVT-1401-2401 clinical trial. Patients must be given accounts by a participating site in order to log in to the app.
Show More
最新バージョン 2.12.7 (33) の更新情報
Last updated on 2024年03月27日
旧バージョン
1) Cohort C eligibility message and functionality during Screening Visit and Visit 13 have been updated per latest protocol.
Inclusion Criteria: Patients have an INCAT score of ≥ 2 points at the Screening and Period 1 Baseline Visits. Note: Participants with an INCAT score of 2 at study entry must have this score exclusively from the leg disability score; for participants with an INCAT score of ≥ 3 at study entry, there are no specific requirements for arm or leg.
2) Site has the ability to make a decision to discontinue the patient from study treatment at the end of any visit if the patient chooses to, regardless of worsening or relapse status, and based on that decision the Clario system will either move the patient to Follow up or the appropriate Early Termination Phase, dependent upon the current visit and whether all Early Termination forms have been completed.
3) Joing Blinded assessor & C-SSRS rater role has been removed from tablet setup.
4) INCAT Score Check Form added in all Visits of Period 1 to monitor Worsening.
Inclusion Criteria: Patients have an INCAT score of ≥ 2 points at the Screening and Period 1 Baseline Visits. Note: Participants with an INCAT score of 2 at study entry must have this score exclusively from the leg disability score; for participants with an INCAT score of ≥ 3 at study entry, there are no specific requirements for arm or leg.
2) Site has the ability to make a decision to discontinue the patient from study treatment at the end of any visit if the patient chooses to, regardless of worsening or relapse status, and based on that decision the Clario system will either move the patient to Follow up or the appropriate Early Termination Phase, dependent upon the current visit and whether all Early Termination forms have been completed.
3) Joing Blinded assessor & C-SSRS rater role has been removed from tablet setup.
4) INCAT Score Check Form added in all Visits of Period 1 to monitor Worsening.
Show More
Version History
2.12.7 (33)
2024年03月27日
1) Cohort C eligibility message and functionality during Screening Visit and Visit 13 have been updated per latest protocol.
Inclusion Criteria: Patients have an INCAT score of ≥ 2 points at the Screening and Period 1 Baseline Visits. Note: Participants with an INCAT score of 2 at study entry must have this score exclusively from the leg disability score; for participants with an INCAT score of ≥ 3 at study entry, there are no specific requirements for arm or leg.
2) Site has the ability to make a decision to discontinue the patient from study treatment at the end of any visit if the patient chooses to, regardless of worsening or relapse status, and based on that decision the Clario system will either move the patient to Follow up or the appropriate Early Termination Phase, dependent upon the current visit and whether all Early Termination forms have been completed.
3) Joing Blinded assessor & C-SSRS rater role has been removed from tablet setup.
4) INCAT Score Check Form added in all Visits of Period 1 to monitor Worsening.
Inclusion Criteria: Patients have an INCAT score of ≥ 2 points at the Screening and Period 1 Baseline Visits. Note: Participants with an INCAT score of 2 at study entry must have this score exclusively from the leg disability score; for participants with an INCAT score of ≥ 3 at study entry, there are no specific requirements for arm or leg.
2) Site has the ability to make a decision to discontinue the patient from study treatment at the end of any visit if the patient chooses to, regardless of worsening or relapse status, and based on that decision the Clario system will either move the patient to Follow up or the appropriate Early Termination Phase, dependent upon the current visit and whether all Early Termination forms have been completed.
3) Joing Blinded assessor & C-SSRS rater role has been removed from tablet setup.
4) INCAT Score Check Form added in all Visits of Period 1 to monitor Worsening.
2.12.6 (27)
2023年11月22日
updated Brazil dosing diary and released batch 6
2.12.5 (23)
2023年09月13日
Language Update
2.12.4 (20)
2023年06月05日
Language update
2.12.3 (16)
2023年05月16日
Added the below languages:
Polish (Poland)
Spanish (United States)
Spanish (Spain)
Catalan (Spain)
Italian (Italy)
Polish (Poland)
Spanish (United States)
Spanish (Spain)
Catalan (Spain)
Italian (Italy)
2.12.2 (13)
2023年04月25日
Language update
2.12.1 (10)
2023年04月07日
IMVT-1401-2401 FAQ
ここをクリック！地理的に制限されているアプリのダウンロード方法をご参考ください。
次のリストをチェックして、IMVT-1401-2401の最低システム要件をご確認ください。
iPhone
iOS 12.0以降が必要です。
iPad
iPadOS 12.0以降が必要です。
iPod touch
iOS 12.0以降が必要です。
IMVT-1401-2401は次の言語がサポートされています。 英語
